UMB Bank n.a. Buys 11,388 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

UMB Bank n.a. lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 44.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 36,933 shares of the medical equipment provider’s stock after purchasing an additional 11,388 shares during the quarter. UMB Bank n.a.’s holdings in Intuitive Surgical were worth $18,144,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC bought a new position in Intuitive Surgical in the 2nd quarter valued at $26,000. Creekmur Asset Management LLC lifted its stake in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the period. LGT Financial Advisors LLC boosted its holdings in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 54 shares during the last quarter. Delos Wealth Advisors LLC increased its position in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares during the period. Finally, LRI Investments LLC bought a new stake in Intuitive Surgical during the 1st quarter worth about $30,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Stifel Nicolaus upped their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Morgan Stanley upped their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. raised their target price on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $454.35.

Intuitive Surgical Price Performance

ISRG stock traded down $6.80 during trading hours on Thursday, reaching $483.58. 234,787 shares of the stock were exchanged, compared to its average volume of 1,467,057. The company has a market cap of $171.53 billion, a price-to-earnings ratio of 88.52, a PEG ratio of 5.39 and a beta of 1.39. The firm’s 50-day moving average is $478.98 and its 200-day moving average is $433.69. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period last year, the company earned $1.18 earnings per share. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,458,979.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock worth $25,528,753 over the last ninety days. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.